A single dose, sequential, randomized, double- blind, placebo-controlled, escalating dose and infusion rate study of Nipocalimab in healthy adults
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Nipocalimab (Primary)
- Indications Autoimmune haemolytic anaemia; Chronic inflammatory demyelinating polyradiculoneuropathy; Haemolytic disease of newborn; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Pharmacokinetics
- 07 Nov 2022 New trial record
- 27 Sep 2022 Results (n=30) presented at the 2022 American College of Clinical Pharmacology Annual Meeting